Biodesix to Present Real-World Clinical and Economic Nodify Lung Data at ATS May 15–20
Biodesix will present real-world clinical and healthcare economic data on its Nodify Lung testing at the American Thoracic Society Annual Meeting, May 15–20, including an oral presentation on May 17 and four poster sessions on May 18–19. The studies involve risk stratification programs in academic and community hospitals.
1. ATS 2026 Presentation Schedule
Biodesix will deliver six sessions during ATS 2026 in Orlando, Florida, May 15–20. The schedule includes an oral presentation by Michael Kammer, PhD, on May 17 at 9:27 AM and five poster sessions on May 18–19, covering blood-based classifiers and risk stratification models at Booth #1327.
2. Clinical and Economic Evidence Highlights
Presentations will showcase real-world clinical outcomes and healthcare economic analyses for the Nodify Lung risk stratification strategy. Case studies from major academic medical centers and community hospitals demonstrate improved lung nodule management, earlier cancer detection, and potential cost savings through Biodesix blood-based testing.